A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice
Launched by ASTELLAS PHARMA EUROPE LTD. · Dec 16, 2014
Trial Information
Current as of May 21, 2025
Completed
Keywords
ClinConnect Summary
Single arm, hybrid model study, observing patients on Betmiga under conditions of routine clinical practice, with some element of retrospective data collection 2 years prior to enrolment of the study
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who have been diagnosed with OAB symptoms at Visit 1 of this study. OAB is defined by the International Urogynecological Association (IUGA)/International Continence Society (ICS) 2010 joint report as urinary urgency, with or without urinary incontinence, usually with frequency and nocturia, with no proven infection or other obvious pathology.
- • Patients whose physician has made the decision to prescribe Betmiga® as part of routine clinical practice and who are about to start treatment.
- Exclusion Criteria:
- • Patients who are currently taking Betmiga®.
- • Contraindication(s) as per the Betmiga® Summary of Product Characteristics (SPC).
About Astellas Pharma Europe Ltd.
Astellas Pharma Europe Ltd. is a leading global pharmaceutical company dedicated to improving the health and quality of life for patients through innovative therapies. With a strong focus on research and development, Astellas specializes in areas such as oncology, urology, immunology, and neuroscience. The company is committed to advancing medical science and addressing unmet medical needs by conducting rigorous clinical trials and collaborating with healthcare professionals and stakeholders. Astellas strives to deliver high-quality medicines that make a meaningful difference in patients' lives across Europe and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brno, , Czechia
Brno, , Czechia
Kyjov, , Czechia
Praha 10, , Czechia
Praha 4, , Czechia
Příbram, , Czechia
Zlín, , Czechia
Frederikshavn, , Denmark
Herning, , Denmark
Heraklion, Crete, Greece
Athens, , Greece
Athens, , Greece
Athens, , Greece
Heraklion, , Greece
Ioannina, , Greece
Ioannina, , Greece
Larisa, , Greece
Patras, , Greece
Thessaloniki, , Greece
Thessaloniki, , Greece
Mullingar, Co. Westmeath, Ireland
Dublin 8, , Ireland
Kerry, , Ireland
Bratislava 3, , Slovakia
Levice, , Slovakia
Liptovský Mikuláš, , Slovakia
Rimavská Sobota, , Slovakia
Trenčín, , Slovakia
Vranov Nad Topľou, , Slovakia
žiar Nad Hronom, , Slovakia
Sabadell, Barcelona, Spain
Mendaro, Guipuzcoa, Spain
Barcelona, , Spain
Barcelona, , Spain
Barcelona, , Spain
Bilbao, , Spain
Burgos, , Spain
Lugo, , Spain
San Sebastian, , Spain
Valladolid, , Spain
Vigo, , Spain
Göteborg, , Sweden
Bradford, , United Kingdom
Burnley, , United Kingdom
Cambridge, , United Kingdom
Chichester, , United Kingdom
Cliftonville, , United Kingdom
Coventry, , United Kingdom
Croydon, , United Kingdom
Derriford, , United Kingdom
Devon, , United Kingdom
Gillingham, , United Kingdom
Glasgow, , United Kingdom
Huntingdon, , United Kingdom
Newcastle Upon Tyne, , United Kingdom
Norfolk, , United Kingdom
Reading, , United Kingdom
Salisbury, , United Kingdom
Sunderland, , United Kingdom
Wolverhampton, , United Kingdom
Patients applied
Trial Officials
Medical Affairs Europe
Study Director
Astellas Pharma Europe Ltd.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials